Denali Therapeutics Inc

Market Cap

$3B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$19.54+$3.27 (+20.10%)

Jun 8, 2026

52W High $22.7452W Low $12.75

Company Details

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for periphera...

CEO

—

IPO Date

Dec 8, 2017

Website

www.denalitherapeutics.com

Key Metrics TTM

Revenue

- YoY

Net Income

-$508M

EPS (Diluted)

Free Cash Flow

-$419M

Revenue / Share

$0.00

Gross Margin

Operating Margin

Net Margin

FCF Margin

P/S

P/E

Earnings Reports

Q2 2026

Aug 10, 2026

PENDING

Q1 2026

May 7, 2026

FY 2025

Feb 26, 2026

Q4 2025

Feb 26, 2026

Q3 2025

Nov 6, 2025

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee